The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | Need for innovative treatments for HL: Creating a benchmark
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses a recent publication on the outcomes of patients with third or higher relapsed classical Hodgkin lymphoma from the German Hodgkin Study Group at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. The study Dr Bröckelmann mentions has allowed for the development of a benchmark for Hodgkin lymphoma and will help a patient group in need of innovative agents.
